Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center - 14/03/18
Doi : 10.1016/j.jaad.2017.11.024
Keshavamurthy Vinay, MD, DNB a, b, ⁎ 
, Simone Cazzaniga, MS a, c, Kyle T. Amber, MD e, Laurence Feldmeyer, MD, PhD a, Luigi Naldi, MD a, c, d, Luca Borradori, MD a
, Simone Cazzaniga, MS a, c, Kyle T. Amber, MD e, Laurence Feldmeyer, MD, PhD a, Luigi Naldi, MD a, c, d, Luca Borradori, MD a a Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
b Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
c Centro Studi GISED, Bergamo, Italy
d Department of Dermatology, San Bortolo Hospital, Vicenza, Italy
e Department of Dermatology, University of California Irvine Health, Irvine, California
∗Reprint requests: Keshavamurthy Vinay, MD, DNB, Department of Dermatology, Inselspital, Bern University Hospital, SwitzerlandDepartment of DermatologyInselspitalBern University HospitalSwitzerland
| Funding sources: Supported by an International Society of Dermatology mentorship grant (to KV) and the Swiss National Science Foundation (grant 310030E-171664; FOR 2497_PEGASUS_TP7 [to LB]). |
|
| Conflicts of interest: None disclosed. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 4
P. 806-808 - avril 2018 Retour au numéro
Article précédent
- Beyond the triad: Inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita
- Suzanne C. Ward, Sharon A. Savage, Neelam Giri, Blanche P. Alter, Philip S. Rosenberg, Dominique C. Pichard, Edward W. Cowen
- Allergen of the Year alkyl glucoside is an ingredient in top-selling sunscreens and facial moisturizers
- Emily Boozalis, Shivani Patel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?